Evotec has entered an exclusive strategic collaboration with the Fraunhofer Institute for internal and external drug discovery projects in several disease areas using a combination platforms from both organizations. The alliance expands Evotec's drug discovery platform with access to a range of platforms and capabilities to use on its own projects and for customers and partners.

Dr. Werner Lanthaler, chief executive officer of Evotec, said, "We are looking forward to partner with Fraunhofer IME and are excited about the potential of this alliance. The IME has an impressive track record for product development and provides an ideal basis for collaborating with one of the strongest science organizations in Germany and beyond. This adds another footprint in Europe of our EVT Innovate programs as we have with U.S.-based academic institutions."